NASDAQ:CLDX
Celldex Therapeutics Stock News
$41.97
+0.180 (+0.431%)
At Close: Mar 28, 2024
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
10:56am, Wednesday, 20'th Mar 2024
The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
10:30am, Tuesday, 05'th Mar 2024
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Infl
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Thursday, 29'th Feb 2024
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
10:56am, Thursday, 29'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positi
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Monday, 26'th Feb 2024
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago.
MoneyShow's Best Investment Ideas For 2024: Part 3
10:45am, Monday, 29'th Jan 2024
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth
MoneyShow's Best Investment Ideas For 2024: Part 2
05:30pm, Friday, 26'th Jan 2024
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
04:15pm, Monday, 27'th Nov 2023
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
01:08pm, Friday, 17'th Nov 2023
The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one's strategic collaboration with a mult
Why Celldex Therapeutics Blasted 13% Higher on Monday
06:47pm, Monday, 06'th Nov 2023
A leading pipeline drug did very well in phase 2 clinical testing. Barzolvolimab met its primary endpoint, and was generally well tolerated.
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
08:15am, Monday, 06'th Nov 2023
Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammator
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
08:31am, Monday, 25'th Sep 2023
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conferenc
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
06:57pm, Tuesday, 08'th Aug 2023
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.58 per share a year ago.
Celldex Therapeutics to Present at Jefferies Healthcare Conference
08:01am, Friday, 02'nd Jun 2023
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
07:44pm, Thursday, 04'th May 2023
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.49 per share a year ago.